

Special Issue

Novel Oligonucleotide Therapeutics and Their Delivery

Message from the Guest Editors

New oligonucleotide therapeutics are becoming increasingly important. Recent approval of parenteral nanoparticle oligonucleotide formulations such as the Pfizer and Moderna COVID RNA vaccines, siRNA therapies such as, givosiran, patisiran, and aptamer therapies like pegaptanib highlight the importance and the increasing success of oligonucleotide delivery. All of these promising oligonucleotide technologies converge on an important requirement: effective drug delivery methods that can get the oligonucleotide drugs into cells and target the drug to the right tissues.

Nanoparticle delivery technology has advanced to meet some of these challenges and newer technologies are being developed that have extended half-lives, and target nanoparticles to particular tissues using “smart” materials, and chemical conjugation. This Special Issue covers the latest information on novel oligonucleotide therapeutics and their delivery. We are seeking original contributions and review articles in these areas.

Guest Editors

Dr. Ted Lakowski

College of Pharmacy, University of Manitoba, Apotex Centre, 750 McDermot Ave. W., Winnipeg, MB R3E 0T5, Canada

Dr. Alejandro Martínez-Águila

R&D Department Avizor Eye Care Solutions, Ocupharm Research Group, Complutense University, 28037 Madrid, Spain

Deadline for manuscript submissions

closed (30 November 2022)



Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



mdpi.com/si/76350

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceuticals and biopharmaceuticals. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, William Levine Hall, Room 225C, 160 Frelinghuysen Road, Piscataway, NJ 08854-8020, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.7 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the second half of 2025).